Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Association of plasma β-amyloid 40 and 42 concentration with type 2 diabetes among Chinese adults

Abstract

Aims/hypothesis

There is evidence for a bidirectional association between type 2 diabetes and Alzheimer’s disease. Plasma β-amyloid (Aβ) is a potential biomarker for Alzheimer’s disease. We aimed to investigate the association of plasma Aβ40 and Aβ42 with risk of type 2 diabetes.

Methods

We performed a case–control study and a nested case–control study within a prospective cohort study. In the case–control study, we included 1063 newly diagnosed individuals with type 2 diabetes and 1063 control participants matched by age (±3 years) and sex. In the nested case–control study, we included 121 individuals with incident type 2 diabetes and 242 matched control individuals. Plasma Aβ40 and Aβ42 concentrations were simultaneously measured with electrochemiluminescence immunoassay. Conditional logistic regression was used to evaluate the association of plasma Aβ40 and Aβ42 concentrations with the likelihood of type 2 diabetes.

Results

In the case–control study, the multivariable-adjusted ORs for type 2 diabetes, comparing the highest with the lowest quartile of plasma Aβ concentrations, were 1.97 (95% CI 1.46, 2.66) for plasma Aβ40 and 2.01 (95% CI 1.50, 2.69) for plasma Aβ42. Each 30 ng/l increment of plasma Aβ40 was associated with 28% (95% CI 15%, 43%) higher odds of type 2 diabetes, and each 5 ng/l increment of plasma Aβ42 was associated with 37% (95% CI 21%, 55%) higher odds of type 2 diabetes. Individuals in the highest tertile for both plasma Aβ40 and Aβ42 concentrations had 2.96-fold greater odds of type 2 diabetes compared with those in the lowest tertile for both plasma Aβ40 and Aβ42 concentrations. In the nested case–control study, the multivariable-adjusted ORs for type 2 diabetes for the highest vs the lowest quartile were 3.79 (95% CI 1.81, 7.94) for plasma Aβ40 and 2.88 (95% CI 1.44, 5.75) for plasma Aβ42. The multivariable-adjusted ORs for type 2 diabetes associated with each 30 ng/l increment in plasma Aβ40 and each 5 ng/l increment in plasma Aβ42 were 1.44 (95% CI 1.18, 1.74) and 1.47 (95% CI 1.15, 1.88), respectively.

Conclusions/interpretation

Our findings suggest positive associations of plasma Aβ40 and Aβ42 concentration with risk of type 2 diabetes. Further studies are warranted to elucidate the underlying mechanisms and explore the potential roles of plasma Aβ in linking type 2 diabetes and Alzheimer’s disease.

This is a preview of subscription content, log in to check access.

Fig. 1

Data availability

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

Aβ:

β-Amyloid

APP:

Amyloid precursor protein

FPG:

Fasting plasma glucose

FPI:

Fasting plasma insulin

HDL-C:

HDL-cholesterol

IAPP:

Islet amyloid polypeptide

LDL-C:

LDL-cholesterol

MSD:

Meso Scale Discovery

NGT:

Normal glucose tolerance

TJEZ:

Tongji-Ezhou cohort

References

  1. 1.

    Chatterjee S, Khunti K, Davies MJ (2017) Type 2 diabetes. Lancet 389(10085):2239–2251. https://doi.org/10.1016/s0140-6736(17)30058-2

  2. 2.

    Zhang J, Chen C, Hua S et al (2017) An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer’s disease. Diabetes Res Clin Pract 124:41–47. https://doi.org/10.1016/j.diabres.2016.10.024

  3. 3.

    Craft S, Zallen G, Baker LD (1992) Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol 14(2):253–267. https://doi.org/10.1080/01688639208402827

  4. 4.

    Fujisawa Y, Sasaki K, Akiyama K (1991) Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry 30(12):1219–1228. https://doi.org/10.1016/0006-3223(91)90158-i

  5. 5.

    Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53(2):474–481. https://doi.org/10.2337/diabetes.53.2.474

  6. 6.

    Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM (2016) Diabetes and Alzheimer’s disease crosstalk. Neurosci Biobehav Rev 64:272–287. https://doi.org/10.1016/j.neubiorev.2016.03.005

  7. 7.

    GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388(10053):1545–1602. https://doi.org/10.1016/s0140-6736(16)31678-6

  8. 8.

    Goate A, Chartier-Harlin MC, Mullan M et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349(6311):704–706. https://doi.org/10.1038/349704a0

  9. 9.

    Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V (2015) Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology 85(13):1123–1130. https://doi.org/10.1212/wnl.0000000000001982

  10. 10.

    Abner EL, Nelson PT, Kryscio RJ et al (2016) Diabetes is associated with cerebrovascular but not Alzheimer’s disease neuropathology. Alzheimers Dement 12(8):882–889. https://doi.org/10.1016/j.jalz.2015.12.006

  11. 11.

    Lu Y, Jiang X, Liu S, Li M (2018) Changes in cerebrospinal fluid tau and β-amyloid levels in diabetic and prediabetic patients: a meta-analysis. Front Aging Neurosci 10:271. https://doi.org/10.3389/fnagi.2018.00271

  12. 12.

    Xiang Y, Bu XL, Liu YH et al (2015) Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease. Acta Neuropathol 130(4):487–499. https://doi.org/10.1007/s00401-015-1477-1

  13. 13.

    Roberts KF, Elbert DL, Kasten TP et al (2014) Amyloid-beta efflux from the central nervous system into the plasma. Ann Neurol 76(6):837–844. https://doi.org/10.1002/ana.24270

  14. 14.

    Zhang Y, Zhou B, Zhang F et al (2012) Amyloid-beta induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 61(6):1434–1443. https://doi.org/10.2337/db11-0499

  15. 15.

    Wijesekara N, Ahrens R, Sabale M et al (2017) Amyloid-beta and islet amyloid pathologies link Alzheimer disease and type 2 diabetes in a transgenic model. FASEB J 31(12):5409–5418. https://doi.org/10.1096/fj.201700431R

  16. 16.

    Zhang Y, Zhou B, Deng B et al (2013) Amyloid-beta induces hepatic insulin resistance in vivo via JAK2. Diabetes 62(4):1159–1166. https://doi.org/10.2337/db12-0670

  17. 17.

    Balakrishnan K, Verdile G, Mehta PD et al (2005) Plasma Aβ42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis 8(3):269–282. https://doi.org/10.3233/jad-2005-8305

  18. 18.

    Kim I, Lee J, Hong HJ et al (2010) A relationship between Alzheimer’s disease and type 2 diabetes mellitus through the measurement of serum amyloid-beta autoantibodies. J Alzheimers Dis 19(4):1371–1376. https://doi.org/10.3233/jad-2010-1332

  19. 19.

    Peters KE, Davis WA, Taddei K et al (2017) Plasma amyloid-β peptides in type 2 diabetes: a matched case-control study. J Alzheimers Dis 56(3):1127–1133. https://doi.org/10.3233/jad-161050

  20. 20.

    Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15(7):539–553. https://doi.org/10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s

  21. 21.

    Chouraki V, Beiser A, Younkin L et al (2015) Plasma amyloid-β and risk of Alzheimer’s disease in the Framingham Heart Study. Alzheimers Dement 11(3):249–257. https://doi.org/10.1016/j.jalz.2014.07.001

  22. 22.

    Iulita MF, Ower A, Barone C et al (2016) An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: relation to cognitive decline and longitudinal evaluation. Alzheimers Dement 12(11):1132–1148. https://doi.org/10.1016/j.jalz.2016.05.001

  23. 23.

    Lambert JC, Schraen-Maschke S, Richard F et al (2009) Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 73(11):847–853. https://doi.org/10.1212/WNL.0b013e3181b78448

  24. 24.

    Yaffe K, Weston A, Graff-Radford NR et al (2011) Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305(3):261–266. https://doi.org/10.1001/jama.2010.1995

  25. 25.

    Mayeux R, Honig LS, Tang MX et al (2003) Plasma Aβ40 and Aβ42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 61(9):1185–1190. https://doi.org/10.1212/01.wnl.0000091890.32140.8f

  26. 26.

    Liu YH, Xiang Y, Wang YR et al (2015) Association between serum amyloid-beta and renal functions: implications for roles of kidney in amyloid-beta clearance. Mol Neurobiol 52(1):115–119. https://doi.org/10.1007/s12035-014-8854-y

  27. 27.

    Chouraki V, De Bruijn RF, Chapuis J et al (2014) A genome-wide association meta-analysis of plasma Abeta peptides concentrations in the elderly. Mol Psychiatry 19(12):1326–1335. https://doi.org/10.1038/mp.2013.185

  28. 28.

    Bates KA, Sohrabi HR, Rodrigues M et al (2009) Association of cardiovascular factors and Alzheimer’s disease plasma amyloid-beta protein in subjective memory complainers. J Alzheimers Dis 17(2):305–318. https://doi.org/10.3233/jad-2009-1050

  29. 29.

    Wang YR, Wang QH, Zhang T et al (2017) Associations between hepatic functions and plasma amyloid-beta levels—implications for the capacity of liver in peripheral amyloid-beta clearance. Mol Neurobiol 54(3):2338–2344. https://doi.org/10.1007/s12035-016-9826-1

  30. 30.

    Stanley M, Macauley SL, Caesar EE et al (2016) The effects of peripheral and central high insulin on brain insulin signaling and amyloid-β in young and old APP/PS1 mice. J Neurosci 36(46):11704–11715. https://doi.org/10.1523/jneurosci.2119-16.2016

  31. 31.

    Swaminathan SK, Ahlschwede KM, Sarma V et al (2017) Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. J Cereb Blood Flow Metab 38(5):904–918. https://doi.org/10.1177/0271678X17709709

  32. 32.

    Tamaki C, Ohtsuki S, Terasaki T (2007) Insulin facilitates the hepatic clearance of plasma amyloid β-peptide (1–40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 72(4):850–855. https://doi.org/10.1124/mol.107.036913

  33. 33.

    Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS (2011) Meta-analysis of plasma amyloid-beta levels in Alzheimer’s disease. J Alzheimers Dis 26(2):365–375. https://doi.org/10.3233/jad-2011-101977

  34. 34.

    Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R (2002) Alzheimer’s β-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22(10):RC221. https://doi.org/10.1523/JNEUROSCI.22-10-j0001.2002

  35. 35.

    Kulas JA, Franklin WF, Smith NA et al (2019) Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues. Am J Phys Endocrinol Metab 316(1):E106–E120. https://doi.org/10.1152/ajpendo.00279.2018

  36. 36.

    O’Nuallain B, Williams AD, Westermark P, Wetzel R (2004) Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 279(17):17490–17499. https://doi.org/10.1074/jbc.M311300200

  37. 37.

    Ono K, Takahashi R, Ikeda T, Mizuguchi M, Hamaguchi T, Yamada M (2014) Exogenous amyloidogenic proteins function as seeds in amyloid beta-protein aggregation. Biochim Biophys Acta 1842(4):646–653. https://doi.org/10.1016/j.bbadis.2014.01.002

  38. 38.

    Miklossy J, Qing H, Radenovic A et al (2010) Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 31(9):1503–1515. https://doi.org/10.1016/j.neurobiolaging.2008.08.019

  39. 39.

    Nortley R, Korte N (2019) Amyloid beta oligomers constrict human capillaries in Alzheimer’s disease via signaling to pericytes. Science 365(6450):eaav9518. https://doi.org/10.1126/science.aav9518

  40. 40.

    Richards OC, Raines SM, Attie AD (2010) The role of blood vessels, endothelial cells, and vascular pericytes in insulin secretion and peripheral insulin action. Endocr Rev 31(3):343–363. https://doi.org/10.1210/er.2009-0035

  41. 41.

    Oh ES, Mielke MM, Rosenberg PB et al (2010) Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-beta in plasma. J Alzheimers Dis 21(3):769–773. https://doi.org/10.3233/jad-2010-100456

  42. 42.

    Stenh C, Englund H, Lord A et al (2005) Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 58(1):147–150. https://doi.org/10.1002/ana.20524

  43. 43.

    Janelidze S, Pannee J, Mikulskis A et al (2017) Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol 74(12):1492–1501. https://doi.org/10.1001/jamaneurol.2017.2814

Download references

Acknowledgements

We thank all participants in the two studies for their tireless dedication. We also thank X. Yu (Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China), and C. Xia and J. Zhang (Health Management Center, Ezhou Center for Disease Control and Prevention, Ezhou, China) for their assistance in data collection.

Authors’ relationships and activities

The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Funding

This work was funded by the National Key Research and Development Program of China (2017YFC1600500), the Major International (Regional) Joint Research Project (NSFC 81820108027) and the National Natural Science Foundation of China (81773423 and 21537001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

XBP, ZX and LL designed the study. XBP, ZX, XM, QG, JY, MX, ZP, TS, LZ, XLP, SX, WY, WB, ZS and XL contributed to the acquisition, analysis or interpretation of data collection. XBP wrote the manuscript. ZX, XM, QG, JY, MX, ZP, TS, LZ, XLP, SX, WY, WB, ZS, XL and LL contributed to reviewing and revising the paper. All authors read and approved the final manuscript. LL is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Correspondence to Xiaoqin Li or Liegang Liu.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM

(PDF 206 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Peng, X., Xu, Z., Mo, X. et al. Association of plasma β-amyloid 40 and 42 concentration with type 2 diabetes among Chinese adults. Diabetologia (2020). https://doi.org/10.1007/s00125-020-05102-x

Download citation

Keywords

  • Alzheimer’s disease
  • β-amyloid 40
  • β-amyloid 42
  • Case–control
  • Nested case–control
  • Type 2 diabetes